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Immunohistochemistry
Formalin-fixed tissues were processed to paraffin, and 4µm sections were deparaffinized, rehydrated, and stained by hematoxylin and eosin (H&E) for histological analysis. Sections were evaluated by a board-certified veterinary pathologist who was blinded to genotype assignments. Staining for T and B cell markers, E-cadherin and vimentin was performed using a standard three-step ABC method. Briefly, after antigen retrieval using pH 6.0 Citrate buffer, sections were then stained for either B cells CD45R/B220 (BD Pharmingen, clone RA3-6B2),
T cells CD3e (Abcam, ab27434), E-cadherin (Cell Signaling, # 3195) or vimentin (Cell Signaling, #5741).
Sections were then stained with either anti-rat or anti-rabbit biotinylated secondary (Caltag) followed by streptavidin ABC (Vector Elite). Slides were developed using DAB/NiCl (Sigma) and counterstained with methyl green. For BrdU staining, paraffin sections were first treated with 2N HCl followed by 0.1% trypsin.
The sections were then stained with an anti-BrdU (DAKO, M0744) primary and an anti-mouse IgG1-HRP (Southern Biotech) secondary. Sections were developed and counterstained as above. The number of BrdU positive cells per 40x field was counted, blind to the genotype, for all tumors in each section.
Immunophenotyping and Cell Cycle Analysis of Lymphomas
Single-cell suspensions were prepared from primary lymphoid tissues using the frosted ends of two glass slides and filtered through a 70µm nylon mesh filter in Iscove's modified Dulbecco's media (IMDM) with 2% fetal calf serum. To identify surface antigens, 0.5-1x10 
Southern Blotting
DNA from MEFs and tumor tissue was isolated using Qiagen Genomic DNA isolation kits as per the manufacturer's instructions. The presence of the wild-type Ctcf allele in Ctcf +/-tumors was determined by Southern blot analysis. Briefly, 10-20 μg of genomic DNA were digested with the restriction enzyme EcoRV (New England Biolabs), separated by linear gel electrophoresis on a 0.8% agarose gel, followed by Southern blotting of the DNA on a hybond-XL membrane (GE Healthcare) and hybridization with the radioactive labeled 5-prime genomic Ctcf probe as described previously (Moore et al., 2012) . Hybridization was performed for a minimum of 16 hours at 65º in a buffer containing 0.125 M Na 2 HPO 4 (pH 7.2), 0.25 M NaCl, 1 mM EDTA, 7%
SDS and 100 μg/ml denatured fish sperm DNA (Roche). After hybridization, membranes were washed with 2x SSC/0.1% SDS, followed by washing with 1x SSC/0.1% SDS and a final wash step with 0.3x SSC/0.1% SDS.
Finally, the membranes were exposed to a phospho-imager screen and signal intensities were analyzed and quantified with ImageQuant software (Molecular Dynamics).
RNA isolation, cDNA generation, and RT-PCR
Total RNA from MEFs and tissues was isolated using TRIzol (Invitrogen) per the manufacturer's instructions, followed by acidic phenol extraction. Prior to RNA extraction, tissue samples were pulverized in the presence of liquid nitrogen to avoid RNA degradation. The isolated RNA was treated with TURBO RNase-free DNase (Ambion) to remove contaminating DNA prior to cDNA generation. cDNA was generated with Superscript III (Invitrogen) under the following conditions. Random hexamers were added to 1-3 g of RNA and incubated at 70° C for 5 minutes in a thermocycler. The temperature was cycled to 50° C and the RNA/primer mixture equilibrated for 5 minutes. Next, the reaction mixture, nuclease free H 2 O, 5X buffer, RNase inhibitor, dNTPs, DTT, and RT (except for no RT control), pre-equilibrated at 50° C, was added to the RNA/primer mixture and incubated for two hours at 50° C, followed by heat inactivation at 70° C for 5 minutes. CTCF expression was analyzed using the following Ctcf primers: Sense: 5' CCTCTGACAGTGAAGAAAATGCTGAGC 3', and
Antisense: 5' GATGGCTGTTGGCTGGTTCTGTTTGGG 3'. Synthesis of cDNA was verified and normalized by amplification of the control GAPDH transcript using primers: Sense: 5' CGTATTGGGCGCCGTGTCACCAGGGC 3', and Antisense: 5' GCCATGAGGTCCACCACCCTGTTGCTG 3'. RNA was tested for DNA contamination using a no-RT control and primers were verified by amplification of genomic DNA
Real-time Polymerase Chain Reaction (PCR)
Real time PCR analysis was performed on the automated ABI 7900 PCR machine (Applied Biosystems) using Fast Start SYBR Green Master Mix (Roche) with ROX passive reference dye added. Ctcf transcript levels in MEFs were analyzed by real time RT-PCR analysis using primers: Ctcf For: 5-TGATGAGAGACCACACAAGTGCCA-3 and Ctcf Rev: 5-CTGCACAAACTGCACTGAAACGGA-3.
cDNA was generated with random hexamers using 1.5 µg RNA, and then diluted 1:1. Two microliters of cDNA was used as template for the real-time reaction. The standard curve assay as described by Applied Biosystems was used for absolute quantification. The values calculated for Ctcf transcript levels were normalized to those of GAPDH in the same samples using primers listed above for cDNA synthesis. of the genomic DNA isolated from the tumor tissue. Each sample was assayed in triplicate. PCR cycling was performed at (94° C/2min, (94° C/30s, 60° C/30s, 72° C/30s) x 40) with an additional ramping step added after cycling to calculate dissociation curves and confirm that fluorescence detected was due to full size PCR product and not PCR artifacts.
Sequencing of Ctcf
Random primed cDNA from RNA isolated from Ctcf +/-tumors was generated as described above under cDNA generation. The Ctcf cDNA was amplified as two overlapping amplicons using primers: 5' GATTTTGCAGCCACGGAGAGGAAGGGGAG 3' and 5' GCACTGGAACGGGCGCTCTCCAGTATGAG 3' for the first amplicon, spanning Ctcf cDNA sequence from the first ATG to zinc finger 4, and 5' GTACTCGTCCTCACAAGTGCCCAGACTGCG 3' and 5' CCAATAGTCCTGGTGCCGAGCAAGGCCCC 3' for the second amplicon spanning Ctcf cDNA sequence from zinc finger 3 to the STOP codon. The resulting PCR amplicons were purified from the gel and then either cloned into the pCR ® 4-TOPO vector (Invitrogen) or directly sequenced using an ABI Prism 3730xl DNA analyzer (Applied Biosystems). Ctcf cDNA amplicons were sequenced in both orientations using a set of primers (five sense and four antisense primers) producing overlapping sequence reads to generate a contiguous Ctcf cDNA sequence for each tumor sample.
Electrophoretic Mobility Shift Assay
DNA fragments, containing known CTCF binding sites at the H19/Igf2 ICR and b-globin insulator FII, were PCR amplified, 32 P-labeled, gel purified, and used as DNA probes for gel mobility shift assays with equal amounts of nuclear extracts isolated from Ctcf
and Ctcf +/+ tissues as previously described (Filippova et al., 2005) . Prior to nuclear extracts isolation, the tissue samples were pulverized in liquid nitrogen to prevent were incubated for 30 min at room temperature and then analyzed on 5% nondenaturing PAGE in the presence of 5% glycerol run in 0.5x Tris-borate-EDTA buffer. Gels were analyzed using a Typhoon phosphoimager (Molecular Dynamics). The intensity of bands was quantified using ImageQuant software.
Bisulfite Sequencing Analysis of DNA Methylation.
Bisulfite treatment of DNA isolated from MEFs and tissues was performed using the EZ DNA Methylation kit (Zymo Research). H19/Igf2 ICR primers recognizing bisulfite converted DNA were designed utilizing the program MethPrimer. Primer sequences are available upon request. PCR was performed in a final volume of 25 μl containing 250 μM dNTPs, 1X Supertag PCR Buffer (HT Biotechnology Ltd), 10 pmol each of forward and reverse primers, and 1 U Silverstar polymerase. Water was used as a control. The cycling conditions were 94° C for 15 min followed by 40 cycles of 94° C for 40 s, 58° C for 40 s, and 72° C for 40 s, and a final extension step of 15 min at 72° C. PCR products were cloned into the pCR ® 4-TOPO vector (Invitrogen) and sequenced using an ABI Prism 3730xl DNA analyzer (Applied Biosystems). At least 20 independent clones per each sample were analyzed by sequencing. SssI methylated DNA was used as a positive control. Briefly, ~1 μg of genomic DNA was methylated at cytosine residues in CpG dinucleotides with SssI methyltransferase (New England Biolabs) in presence of 0.8 mM S-adenosyl methionine for 16 hours followed by heat inactivation. The levels of bisulfite conversion were estimated by the analysis of non-CpG cytosines. Only samples with > 98% bisulfite conversions were analyzed for the levels of CpG methylation.
Mouse Embryo Fibroblasts
Mouse embryo fibroblasts (MEFs) were derived from E13.5 -E14.5 embryos and cultured according to the standard 3T3 protocol. Passage 7-9, Ctcf
and Ctcf
+/+
MEFs derived from littermates were grown to confluence and foci were documented after 15-20 days in culture (Bowman et al., 2001 ). All assays were performed in triplicate. Cell proliferation was analyzed using CellTiter 96 Aqueous One Solution Cell
Proliferation Assay (Promega). 500 or 1000 cells/well were plated in 96-well plates and cultured for 6 days.
Each day, 20 µl of the MTS solution was added directly to corresponding culture wells, incubated for 3 hours and viable cells were assayed by recording absorbance at 490 nm with a 96-well plate reader. The assay was performed in six replicates with empty media as a base line control. For cell cycle analysis, 1x10 6 cells were fixed in 70% ethanol at -20C for 1 hour, washed twice with 2% FCS/PBS, and stained with 25µg/ml propidium iodide, 1mg/ml RNaseA in 2% FCS/PBS overnight at 4C. Samples were acquired on a FACScan and DNA content analyzed using Cellquest Software (Becton Dickinson, Mountain View, CA).
Enhanced Reduced Representation Bisulfite Sequencing (ERRBS)
The amplified libraries were sequenced using a 50-bp single end read run on a HiSeq2000 Illumina (San Diego, CA, USA) as per manufacturer's recommended protocol. Image capture, analysis, and base calling were performed using Illumina's CASAVA 1.7, Illumina. Hierarchical clustering of lung samples was performed using the hclust function, applying Manhattan distance and Ward's minimum variance method, and PCA was performed using the prcomp function in in R-2.15.2 (http://www.r-project.org/). Genomic distribution of CpGs was determined using the ChIPseeqerAnnotate module in the ChIPseeqer package (Giannopoulou and Elemento, 2011 (Wang et al., 2010) . The ranking of mutations for these tumor types was taken from the MutSig algorithm (https://confluence.broadinstitute.org/display/CGATools/MutSig, REF5. Broad
Firehose Analysis Run 20120913, http://gdac.broadinstitute.org/runs/analyses__2012_09_13/), which calculates the probability of seeing the observed set of mutations for a given gene given the background mutation rates across the complete dataset.
The GISTIC2 algorithm (Mermel et al., 2011) was used to identify samples with significant somatic gains or losses of CTCF in breast invasive carcinoma and uterine corpus endometrioid carcinoma. Diploid samples had a value of zero, and all non-zero values represented the number of copies gained or lost. Non-integer values represent sub-clonal gain or loss. Methylation beta-values were calculated as the fraction (ranging from 0 to 1) of methylated beads from the Illumina Infinium DNA methylation platform, taken from Level 3 TCGA data.
The methylation analysis pipeline for generating these Level 3 data has been previously described (The Cancer Genome Atlas Network, 2012a; The Cancer Genome Atlas Network, 2012b).
Endometrial and breast tumors were analyzed in three classes: (i) samples with CTCF copy number aberration (CNA) less than -0.25, (ii) samples with CTCF somatic mutations (SM), and (iii) samples that were CTCF diploid (GD). To identify DNA methylation probes with CTCF-associated differential methylation, the average methylation was first calculated for each class at each methylation probe. Next, the differences in average methylation at each methylation probe between the CNA-GD and the SM-GD groups were calculated, such that positive values represented hypermethylation and negative values represented aberrant hypomethylation. The significance of these average methylation values for each probe was then determined by permuting the class labels 10,000 times and estimating the p-value by fitting the permutation test values to a generalized Pareto distribution (Knijnenburg et al., 2009 ) with the optimal order preserving transform (Knijnenburg et al., 2011) .
Not all tumors had mutation, copy number and DNA methylation data which explains the discrepancy in the number of samples analyzed in each category. TCGA level 3 data was used to correlate CTCF mRNA levels with DNA copy number and to obtain survival data.
